China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with US firm Boston Scientific Group plc (BSG, NYSE: BSX), signaling their intention to explore collaboration in multiple fields, including research and development (R&D), manufacturing, and marketing and sales. Financial details of the agreement were not disclosed. Notably, Boston Scientific took a majority ownership stake in Acotec in a December 2022 deal worth USD 523 million.
Leveraging Complementary Strengths for Collaboration
The two companies will leverage their respective advantages in science, technology, expertise, and resources to strengthen their collaboration. The focus will be on:
- Research and Development of Cardiovascular Diseases: They will work together to develop products for the United States, China, Japan, European countries, and other markets, targeting the treatment of chronic total occlusion (CTO) lesions, lower limb arterial stenosis, varicose veins, and maintenance of dialysis patient pathways.
- Manufacturing and Cost-Effectiveness: Several products will be manufactured based on original equipment manufacturer (OEM) standards, aiming to achieve cost-effectiveness for both parties.
- Cross-Selling and Intermodal Products: They will cross-sell several products or launch intermodal products in peripheral, coronary artery, tumor, urology, and other fields to maximize channel utilization and enhance product value.
- Product Regulatory Filing Support: The collaboration will also involve supporting each other in product regulatory filings to ensure smooth market entries.-Fineline Info & Tech
